ASH 2025: Kelonia Therapeutics presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation
Founder and CEO Kevin Friedman describes Kelonia's approach, which uses a lentivirus for delivery, and discusses differentiating features of in vivo CAR-T platforms. He walks us through today's data and highlights what is next.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.